Vyvgart

Chemical Nameefgartigimod alfa-fcab
Dosage FormInjection (intravenous; (20 mg/mL)
Drug ClassReceptor antagonists
SystemMusculoskeletal
CompanyArgenx
Approval Year2021

Indication

  • For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Last updated on 2/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyvgart (efgartigimod alfa-fcab) Prescribing Information.2021argenx BV, Zwijnaarde, Belgium